CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:A novel predictive algorithm to personalize autologous T-cell harvest for chimeric antigen receptor T-cell manufacture.
A novel predictive algorithm to personalize autologous T-cell harvest for chimeric antigen receptor T-cell manufacture.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
作者提出了一种可迁移的模型,该模型纳入了采集前可获取的临床和实验室变量,适用于 T 细胞治疗领域。在进一步验证之前,该模型可用于制定个体化白细胞采集计划,并简化细胞采集流程——这是业内公认的瓶颈。
目前最广泛接受的CAR-T 细胞制备起始材料是通过白细胞分离术(也称为T细胞采集)获得的自体CD3+ T细胞。随着这种治疗模式的发展势头增强,而单采单位难以满足采集名额的需求,简化这一关键步骤的策略势在必行。
这项对262份T细胞采集物的回顾性分析,以健康供者作为对照队列,分析了影响B细胞恶性肿瘤成人患者CD3+ T细胞产量的参数。总体目标是设计一种新的预测算法,以指导单采机上所需处理血量(PBV)(L),从而达到特定的CD3+目标产量。
多因素分析中与CD3+ T细胞产量相关的因素包括外周血CD3+计数(自然对数,10 9 /L)、血细胞比容(HCT)和PBV,其系数分别为0.86(95%置信区间[CI],0.80-0.92,P < 0.001)、1.30(95% CI,0.51-2.08,P = 0.001)和0.09(95% CI,0.07-0.11,P < 0.001)。作者的模型结合了CD3+细胞计数、HCT和PBV(L),在训练数据集中调整R 2为0.87,均方根误差为0.26,在测试数据集中对CD3+细胞产量具有高度预测性。使用该算法估算PBV的在线应用程序可访问https://cd3yield.shinyapps.io/cd3yield/。
This retrospective review of 262 T-cell harvests, with a control cohort of healthy donors, analyzed the parameters impacting CD3+ T-cell yield in adults with B-cell malignancies. The overall aim was to design a novel predictive algorithm to guide the required processed blood volume (PBV) (L) on the apheresis machine to achieve a specific CD3+ target yield.
Factors associated with CD3+ T-cell yield on multivariate analysis included peripheral blood CD3+ count (natural log, 10 9 /L), hematocrit (HCT) and PBV with coefficients of 0.86 (95% confidence interval [CI], 0.80-0.92, P < 0.001), 1.30 (95% CI, 0.51-2.08, P = 0.001) and 0.09 (95% CI, 0.07-0.11, P < 0.001), respectively. The authors' model, incorporating CD3+ cell count, HCT and PBV (L), with an adjusted R 2 of 0.87 and root-mean-square error of 0.26 in the training dataset, was highly predictive of CD3+ cell yield in the testing dataset. An online application to estimate PBV using this algorithm can be accessed at https://cd3yield.shinyapps.io/cd3yield/.
The authors propose a transferrable model that incorporates clinical and laboratory variables accessible pre-harvest for use across the field of T-cell therapy. Pending further validation, such a model may be used to generate an individual leukapheresis plan and streamline the process of cell harvest, a well-recognized bottleneck in the industry.
MEMBER ACCOUNT
登录成功会直接打开下一页。